Date : 11/02/2010 @ 5:00PM
Source : GlobeNewswire Inc.
Stock : Discovery Laboratories, Inc. (DSCO)
http://ih.advfn.com/p.php?pid=nmona&article=45045634
Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that it will be hosting a conference call on Tuesday, November 9, 2010, at 10:00 AM EST. Management will provide a pipeline and business update addressing:
* Status of program to gain FDA approval for Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants
* Status of key pipeline programs including: additional data analysis from the recently completed comprehensive analysis of the Phase 2 clinical trial of Surfaxin in children with Acute Respiratory Failure (ARF); review of recently completed Phase 2a clinical study of aerosolized KL4 surfactant in patients with cystic fibrosis (CF); update of next generation RDS programs – Surfaxin LS™ and Aerosurf®
* Strategic initiatives and financial overview
Participants are encouraged to access this audio webcast through a live broadcast on the Company's website at www.discoverylabs.com. The webcast is also accessible on the Internet: http://us.meeting-stream.com/discoverylabs_110910. It is recommended that participants log onto one of these sites at least 15 minutes prior to the call. The Internet broadcast will be available for up to 90 days after the call at both website addresses.
The call in number is 866-332-5218. The international call in number is 706-679-3237. A replay of the conference call will be available two hours after the call's completion and remain available through November 16, 2010. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 22279770.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
CONTACT: Linnden Communications
Media relations:
Michelle Linn
508-362-3087
Discovery Laboratories, Inc.
Investor relations:
John G. Cooper, President and Chief Financial Officer
215-488-9490
Recent WINT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:59:51 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/09/2024 12:41:34 PM
- Windtree Therapeutics Regains Compliance with Nasdaq • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Windtree Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing • GlobeNewswire Inc. • 04/08/2024 08:48:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:07:43 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/14/2024 10:23:27 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:30:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:15:54 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 09:40:42 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 10:26:23 PM
- Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives • InvestorsHub NewsWire • 01/31/2024 01:40:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 01:00:12 PM
- Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company • InvestorsHub NewsWire • 01/25/2024 02:04:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 01:34:03 PM
- Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:45:14 PM
- Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 12:56:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/16/2024 09:16:06 PM
- Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator • GlobeNewswire Inc. • 01/02/2024 09:05:00 PM
- Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock • GlobeNewswire Inc. • 12/18/2023 01:00:00 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM